{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:06:14Z","timestamp":1771045574273,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to evaluate the activity of selinexor, an oral selective inhibitor of nuclear export, in patients with recurrent or metastatic salivary gland tumors (SGT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>GEMS\u2010001 is an open\u2010label Phase 2 study for patients with recurrent or metastatic SGT with two parts. In Part 1 of the protocol, patients had tumor samples profiled with targeted next generation sequencing as well as immunohistochemistry for androgen receptor, HER\u20102 and ALK. For Part 2, patients with no targeted therapies available were eligible to receive selinexor 60\u2009mg given twice weekly every 28\u2009days. The primary endpoint was objective response rate. Secondary endpoints included progression\u2010free survival (PFS) and prevalence of druggable alterations across SGT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred patients were enrolled in GEMS\u2010001 and underwent genomic and immunohistochemistry profiling. A total of 21 patients who lacked available matched therapies were treated with selinexor. SGT subtypes (WHO classification) included adenoid cystic carcinoma (<jats:italic>n<\/jats:italic>\u2009=\u200910), salivary duct carcinoma (<jats:italic>n<\/jats:italic>\u2009=\u20093), acinic cell carcinoma (<jats:italic>n<\/jats:italic>\u2009=\u20092), myoepithelial carcinoma (<jats:italic>n<\/jats:italic>\u2009=\u20092), carcinoma ex pleomorphic adenoma (<jats:italic>n<\/jats:italic>\u2009=\u20092) and other (n\u2009=\u20092). Of 18 evaluable patients, stable disease (SD) was observed in 17 patients (94%) (SD \u22656\u2009months in 7 patients (39%)). However, no objective responses were observed. The median PFS was 4.9\u2009months (95% confidence interval, 3.4\u201310). The most common treatment\u2010related Grade 1\u20132 adverse events were nausea [17 patients (81%)], fatigue [16 patients (76%)], and dysgeusia [12 patients (57%)]. Most common treatment\u2010related Grade 3\u20134 adverse events were hyponatremia [3 patients (14%)], neutrophil count decrease [3 patients (14%)] and cataracts [2 patients (10%)]. No treatment\u2010related deaths were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although tumor reduction was observed across participants, single agent selinexor anti\u2010tumor activity was limited.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6589","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T05:20:35Z","timestamp":1697088035000},"page":"20299-20310","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the <scp>GEMS<\/scp>\u2010001 clinical trial"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-1125","authenticated-orcid":false,"given":"Alberto","family":"Hernando\u2010Calvo","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-7141","authenticated-orcid":false,"given":"Eoghan","family":"Malone","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Day","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Prawira","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Weinreb","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Y. Cindy","family":"Yang","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horace","family":"Wong","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Jennings","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneli","family":"Eliason","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-008-0882-7"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1192"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2018.04.004"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2320-6"},{"key":"e_1_2_13_6_1","unstructured":"HowladerN NooneAM KrapchoM et al.SEER Cancer Statistics Review 1975\u20132017.2020https:\/\/seer.cancer.gov\/csr\/1975_2017\/"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580141"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0031"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6503"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01859"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.12.3747"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1936-z"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.e13549"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30686-1"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25088"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5637"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1998.tb03905.x"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(96)90316-0"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3949"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.6081"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24745"},{"issue":"5","key":"e_1_2_13_22_1","first-page":"3781","article-title":"Paclitaxel and carboplatin for recurrent salivary gland malignancies","volume":"20","author":"Airoldi M","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10034"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx399"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4554"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25637"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28047"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.6097"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221126151"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:20:31Z","timestamp":1741749631000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/cam4.6589"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6589","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}